Beijing Innocare Pharma Tech Co., Ltd.

This early-stage trial tests a new drug (ICP-248) combined with a standard chemotherapy (azacitidine) in people with acute myeloid leukemia or myelodysplastic syndromes. The goal is to find a safe dose and see if the combo helps control the disease. About 266 adults will take par…

This study tests an experimental drug called ICP-332 in people with moderate to severe chronic spontaneous urticaria (long-term hives) that don't get better with standard antihistamines. About 344 adults will receive either the drug or a placebo to see if it reduces itching and w…

This study tests an oral medication called ICP-488 in 383 adults with moderate to severe plaque psoriasis. Participants take the drug or a placebo daily for 16 weeks. The main goal is to see if the drug can make skin clear or almost clear. This is a Phase 3 trial, meaning it is o…

This study tests an experimental drug called ICP-248 in 75 adults with mantle cell lymphoma that has returned or stopped responding to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. Participants will receive the drug and be monitor…

This study tests whether a new drug (orelabrutinib) plus rituximab works better than a standard combination (lenalidomide plus rituximab) for adults with marginal zone lymphoma that has come back or stopped responding to treatment. About 324 participants will receive one of the t…

This study tests an experimental drug called ICP-332 in 135 adults with prurigo nodularis, a skin condition causing intensely itchy bumps. Participants will receive either the drug or a placebo for 16 weeks. The main goal is to see if the drug reduces worst-itch scores on a 0–10 …

This study tests an experimental drug called ICP-332 against a placebo in 172 adults with moderate-to-severe plaque psoriasis. The goal is to see if the drug can reduce psoriasis symptoms by at least 75% after 12 weeks. Participants must have had psoriasis for at least 6 months a…

This early-stage study tests whether the experimental drug ICP-538 is safe and tolerable in healthy adults. About 104 participants will receive either the drug or a placebo, and researchers will monitor for side effects and how the drug moves through the body. This study does not…